Why the study?
Few studies have examined the relationship between acupuncture and changes in inflammatory biomarkers in major depressive disorder, and findings remain inconsistent.
Does acupuncture affect peripheral inflammatory cytokines in patients with major depressive disorder?
Does acupuncture affect peripheral inflammatory cytokines in patients with major depressive disorder?
This is a protocol for a systematic review and meta-analysis to evaluate the effect of acupuncture on inflammatory cytokines in patients with major depressive disorder.
May support adjunctive acupuncture to modulate inflammation in MDD; extends sparse biomarker data but leaves clinical translation open.
Background: Acupuncture is widely used as adjuvant therapy for major depressive disorder (MDD). There is robust evidence that inflammation is closely associated with MDD. To date, only a few numbers of studies have investigated the potential relationship between acupuncture and the change of inflammatory biomarkers in patients with MDD. Additionally, the results are inconsistent among studies. The current study aims to provide a comprehensive, systematic review of the association between acupuncture and changes in peripheral inflammation of patients with MDD, and clarify the alterations of inflammatory cytokines before and after acupuncture treatment by meta-analysis. Methods and analysis: This study will be conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Eligible randomized controlled trials (RCTs) reporting acupuncture, with inflammatory cytokines as the outcome measured before and after intervention in patients with MDD, were searched in electronic databases, such as PubMed, Embase, Cochrane, SINOMED, Wanfang, China national knowledge infrastructure (CNKI), and Chongqing VIP (CQVIP). Primary outcomes of interest will be validated to measure the levels of inflammatory cytokines before and after acupuncture treatment in patients with MDD. Discussion: Acupuncture can drive anti-inflammatory effects, as well as symptom changes in MDD, which may represent a viable, multi-faceted treatment approach in MDD. Systematic review registration: [PROSPERO], identifier [CRD42021289207 on 04 December 2021].
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: